{"title": "Vaccines", "author": null, "url": "https://www.contemporarypediatrics.com/clinical/vaccines", "hostname": "contemporarypediatrics.com", "description": null, "sitename": "Contemporary Pediatrics", "date": "2020-03-26", "cleaned_text": "August 30th 2023 According to a recent Morbidity and Mortality Weekly Report, the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years. July 31st 2023 [FDA approves 20-valent pneumococcal conjugate vaccine for infants 6 weeks and older](/view/fda-approves-20-valent-pneumococcal-conjugate-vaccine-for-infants-6-weeks-and-older) According to Pfizer, the company's pneumococcal conjugate vaccine Prevnar 20 has been approved by the FDA to treat infants and children aged 6 weeks to 17 years for the prevention of invasive pneumococcal disease (IPD). [Half of meningococcal vaccination appointments delayed or canceled during COVID-19 pandemic](/view/half-of-meningococcal-vaccination-appointments-delayed-or-canceled-during-covid-19-pandemic) A multi-country survey revealed 50% of meningitis vaccination appointments were delayed or canceled amid the COVID-19 pandemic, highlighting the need for \"urgent action\" to maintain routine vaccination levels among children, according to survey authors. [FDA authorizes bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for children 6 months through 4 years of age](/view/fda-authorizes-bivalent-pfizer-biontech-covid-19-vaccine-as-booster-dose-for-children-6-months-through-4-years-of-age-) A new booster shot of the Pfizer-BioNTech COVID-19 vaccine is now available for young children to help protect this population against serious COVID-19 effects. [Effectiveness of monovalent mRNA vaccines against COVID-19 in young children](/view/effectiveness-of-monovalent-mrna-vaccines-against-covid-19-in-young-children) In a recent report from the CDC, monovalent vaccines from Moderna and Pfizer have shown vaccine effectiveness in children aged 3 to 5 years in at least the first 4 months after vaccination. [Bivalent COVID-19 booster safety profile consistent with monovalent vaccine](/view/bivalent-covid-19-booster-safety-profile-consistent-with-monovalent-vaccine) The Centers for Disease Control and Prevention has provided an updated safety profile on the bivalent COVID-19 booster vaccine in children aged 5 to 11 years, showing similar adverse events to the monovalent vaccine. [COVID-19 vaccine safe 90 days after MIS-C diagnosis ](/view/covid-19-vaccine-safe-90-days-after-mis-c-diagnosis) Patients with a history of multisystem inflammatory syndrome in children (MIS-C) completed a questionnaire about adverse reactions following COVID-19 vaccination, and no serious adverse events were recorded. [Effectiveness of cell-based vaccines against influenza](/view/effectiveness-of-cell-based-vaccines-against-influenza) Deborah Molrine, MD, discusses CSL Seqirus' cell-based quadrivalent seasonal influenza vaccine, along with the effectiveness of cell-based vaccines in children. [FDA grants emergency use authorization to Moderna's COVID-19 booster in pediatric patients](/view/fda-grants-emergency-use-authorization-to-moderna-s-covid-19-booster-in-pediatric-patients) Moderna has announced that their latest BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, has been granted Emergency Use Authorization by the US Food and Drug Administration. "}